Indian pediatrics · 2026
Trends in Weight and Triceps Skinfold Thickness During Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Selvan Monica, Ramamoorthy Jaikumar Govindaswamy
Аннотация
OBJECTIVE: To assess the weekly trends in weight and triceps skinfold thickness (TSFT) in children with acute lymphoblastic lymphoma (ALL) during induction chemotherapy.
METHODS: Children aged 1 month to 15 years with ALL were followed up during induction phase of chemotherapy. Weight and TSFT were recorded at baseline and on days 8, 15, 22, 29, and 35 and trends of the same were analyzed.
RESULTS: A total of 101 children with median (q1, q3) age 6 (3, 11) years were assessed at baseline, and 95 were assessed on day 8 of induction. The weight loss and TSFT depletion were observed in 74 (77.8%) and 60 (63.1%), respectively, at any time during induction, peaking in severity within the first week of induction therapy. Treatment interruptions were observed in 60.8% children who had weight loss and/or TSFT depletion. Almost 54% and 42% children did not regain baseline weight and TSFT by the end of induction. Standard risk and age < 6.5 years were associated with decreased risk of weight loss and TSFT depletion.
CONCLUSION: Older children are prone to weight loss and sarcopenic wasting during induction phase of chemotherapy for ALL.
METHODS: Children aged 1 month to 15 years with ALL were followed up during induction phase of chemotherapy. Weight and TSFT were recorded at baseline and on days 8, 15, 22, 29, and 35 and trends of the same were analyzed.
RESULTS: A total of 101 children with median (q1, q3) age 6 (3, 11) years were assessed at baseline, and 95 were assessed on day 8 of induction. The weight loss and TSFT depletion were observed in 74 (77.8%) and 60 (63.1%), respectively, at any time during induction, peaking in severity within the first week of induction therapy. Treatment interruptions were observed in 60.8% children who had weight loss and/or TSFT depletion. Almost 54% and 42% children did not regain baseline weight and TSFT by the end of induction. Standard risk and age < 6.5 years were associated with decreased risk of weight loss and TSFT depletion.
CONCLUSION: Older children are prone to weight loss and sarcopenic wasting during induction phase of chemotherapy for ALL.